Preliminary anti-leukemia activity from A phase 1 study of cln-049, a novel anti-FLT3 x anti-CD3 bispecific T-cell engager, in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and myelodysplastic syndrome (MDS)
Year: 2025
Type: conference-abstract
Source: Blood
Authors: Maher Abdul-Hay, Colin Vale, Onyee Chan, Namrata Chandhok, Courtney DiNardo, Gary Schiller, Eunice Wang, Sanghee Hong, Kimo Bachiashvili, Mohammed Chaudhry, Kristy Kuplast-Barr, Kaida Wu, Todd Shearer, Thuy Hoang, Irina Shapiro, Máire Quigley, Jeffrey Jones, William Blum, David Sallman, Ghayas Issa
Institutions: NYU Langone Health, New York University, Emory University, Winship Cancer Institute, Moffitt Cancer Center, University of Miami, Sylvester Comprehensive Cancer Center, The University of Texas MD Anderson Cancer Center, University of California, Los Angeles, Roswell Park Comprehensive Cancer Center, Duke University, Duke Medical Center, University of Alabama at Birmingham, O'Neal Comprehensive Cancer Center
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4417001979